Audentes Therapeutics — Technical Presentation (October 2018)
20 slides from Audentes Therapeutics's technical presentation, Oct 5, 2018
Slide 1: ASPIRO Phase 1/2 Gene Therapy Trial in XLMTM: Preliminary Safety and Efficacy Findings
ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Preliminary Safety and Efficacy Findings Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause event
Slide 3: X-Linked Myotubular Myopathy (XLMTM)
1. Raess MA, et al. Adv Biol Regul 2017;63:49–58 2. Buj-Bello A, et al. PNAS 2002;99:15060–5 3. Di Paolo G, et al. Nature 2006;443:651–7 4. Hnia K, et al. J Clin Invest 2011;121:70–85 5. Amoasii L, et al. J Cell Sci 2013;126(Pt 8):1806–19 6. Lawlor M, et al. J Neuropathol Exp Neurol 2016;75(5):479 X
Slide 4: XLMTM: A fatal disease with no treatment options
Beggs AH, et al. Muscle Nerve 2018;57:550–60 Jungbluth H, et al. Orphanet J Rare Dis. 2008;3:26 Vandersmissen I, et al. Neuromuscul Disord 2018;28:766–77 Mack DL, et al. Mol Ther 2017;25:839–54 Hnia K, et al. J Clin Invest 2011;121:70–85 X-Linked Myotubular Myopathy (XLMTM) A fatal disease with no t
Slide 5: ASPIRO Phase 1/2 Clinical Study of AT132
ASPIRO Phase 1/2 Clinical Study of AT132 (rAAV8-Des-hMTM1) Open-label, ascending-dose, safety and preliminary efficacy study Updated as of September 26, 2018 Inclusion criteria Subject is male <5 years old, or enrolled in INCEPTUS Genetically confirmed XLMTM Requires ventilator support Key efficacy
Slide 6: Safety and Tolerability
Safety and Tolerability
Slide 7: AT132 Cumulative Safety and Tolerability Profile
AT132 Cumulative Safety and Tolerability Profile No tolerability issues and no treatment-related SAEs since last update in August 2018 Extended steroid coverage in Cohort 1 expansion potentially associated with fewer AEs aUntreated control; b34 non-treatment related, non-serious AEs Cohort 1: 1 x 10
Slide 8: Neuromuscular Function: CHOP INTEND and Developmental Milestones
Neuromuscular Function CHOP INTEND and Developmental Milestones
Slide 9: Significant Improvements in Neuromuscular Function
CHOP INTEND score Cohort #: Patient # Baseline score in ASPIRO Most recent score Change from baseline, score (%) 29 56 (Wk 48) +27 (+93%) 45 64 (Wk 48) +19 (+42%) 34 34 (Wk 36) 0 (0%)* 36 53 (Wk 24) +17 (+47%) 39 52 (Wk 16) +13 (+33%) 43 53 (Wk 16) +10 (+23%) 49 47 (Wk 36) -2 (-4%) 36 55 (Wk 4) +19
Slide 10: Motor Milestones
Motor Milestones Achieved and maintained multiple motor developmental milestones aCohort 1: 1 x 1014 vg/kg; bCohort 2: 3 x 1014 vg/kg; cAge at ASPIRO baseline; dLimited by halo traction device for treatment of pre-existing scoliosis BL, ASPIRO baseline; W, week Interim data as of September 26, 2018
Slide 11: Respiratory Function: Maximal Inspiratory Pressure and Ventilator Dependence
Respiratory Function Maximal Inspiratory Pressure and Ventilator Dependence
Slide 12: Significant Improvements in Respiratory Function
Maximum inspiratory pressure (cmH2O) Cohort #: Patient # Baseline MIP in ASPIRO Most recent MIP Change from baseline 33 89 (Wk 24)* +170% 44 112 (Wk 48) +155% 26 70 (Wk 24) +170% 14 78 (Wk 24) +457% 35 87 (Wk 12) +149% 29 68 (Wk 12) +134% 58 46 (Wk 24) -21% 31 67 (Wk 4) +116% Significant Improvement
Slide 13: Significant Reductions in Ventilator Use in All Patients by Week 24
Ventilator status Cohort #: Patient # Status at baseline (h/day) Most recent status Change from baseline BiPAP (12h) 0 (Wk 48) -100% Inv (22h) 6 (Wk 48) -73% Inv (24h) 0 (Wk 40) -100% Inv (24h) 12 (Wk 24) -50% Inv (24h) 0 (Wk 20) -100% Inv (23.5h) 10 (Wk 20) -57% BiPAP (12h) 12 (Wk 36) 0% Inv (22.5h
Slide 14: Muscle Biopsy
Muscle Biopsy
Slide 15: Muscle Biopsy: Vector Copy Number and Myotubularin Expression
Muscle Biopsy: Vector Copy Number and Myotubularin Expression Robust tissue transduction and myotubularin expression at 1 ´ 1014 vg/kg Interim data as of September 20, 2018 Cohort 1: AT132 1 x 1014 vg/kg dg, diploid genome; WT, wild type *The standard is currently being titrated and the linear range
Slide 16: Histological Improvements
Cohort 1: 1 x 1014 vg/kg H&E, hematoxylin and eosin; NADH, nicotinamide adenine dinucleotide Histological Improvements Week 24 biopsies show significantly improved organelle and nuclear localization Patient 2 Normal 4 Year Old Baseline Week 24 H&E NADH
Slide 17: Histological Improvements
Patient 2 Baseline Week 24 H&E NADH Patient 3 Baseline Week 24 H&E NADH Patient 1 Baseline Week 24 H&E NADH Patient 5 Baseline Week 24 H&E NADH Structural improvements were consistent at week 24 for all treated patients Histological Improvements Cohort 1: 1 x 1014 vg/kg H&E, hematoxylin and eosin; N
Slide 18: Patient Videos
Patient Videos Please: No photographic or video recordings of patient videos
Slide 19: ASPIRO Key Findings and Program Next Steps
ASPIRO Key Findings and Program Next Steps DMC, data monitoring committee AT132 has been well tolerated and has shown a manageable safety profile to date at doses up to 3 ´ 1014 vg/kg Rapid and significant improvements in neuromuscular and respiratory function Clinically meaningful improvements in C
Slide 20: ASPIRO Phase 1/2 Gene Therapy Trial in XLMTM: Preliminary Safety and Efficacy Findings
ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Preliminary Safety and Efficacy Findings
Audentes Therapeutics — Technical Presentation (October 2018) on 6ix